Reduced Levels of Protein Tyrosine Phosphatase CD45 Protect Mice from the Lethal Effects of Ebola Virus Infection  by Panchal, Rekha G. et al.
Cell Host & Microbe
ArticleReduced Levels of Protein Tyrosine
Phosphatase CD45 Protect Mice
from the Lethal Effects of Ebola Virus Infection
Rekha G. Panchal,1,* Steven B. Bradfute,1 Brian D. Peyser,1 Kelly L. Warfield,1 Gordon Ruthel,1 Douglas Lane,2
Tara A. Kenny,2 Arthur O. Anderson,1 William C. Raschke,3,4 and Sina Bavari1,*
1United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702-5011, USA
2Target Structure Based Drug Discovery Group, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD, 21702-1201, USA
3Sidney Kimmel Cancer Center, 10905 Road to the Cure, San Diego, CA 92121, USA
4Virogenics, Inc., P.O. Box 2702, Del Mar, CA 92104, USA
*Correspondence: rekha.panchal@amedd.army.mil (R.G.P.), sina.bavari@amedd.army.mil (S.B.)
DOI 10.1016/j.chom.2009.07.003SUMMARY
Ebola virus (EBOV) infection of humans is a lethal but
accidental dead-end event. Understanding resis-
tance to EBOV in other species may help establish
the basis of susceptibility differences among its
hosts. Although rodents are resistant to EBOV, a
murine-adapted variant is lethal when injected intra-
peritoneally into mice. We find that mice expressing
reduced levels of the tyrosine phosphatase CD45
are protected against EBOV, whereas wild-type,
CD45-deficient, or enzymatically inactive CD45-
expressing mice succumbed to infection. Protection
was dependent on CD8+ T cells and interferon g.
Reduced CD45-expressing mice retained greater
control of gene expression and immune cell prolifer-
ation following EBOV infection, which contributed to
reduced apoptosis, enhanced viral clearance, and
increased protection against the virus. Together,
these findings suggest that host susceptibility to
EBOV is dependent on the delicate balance of
immune homeostasis, which, as demonstrated here,
can be determined by the levels of a single regulator.
INTRODUCTION
Ebola virus (EBOV), a member of the family Filoviridae, is
a single-stranded, negative-sense RNA virus that can cause
acute hemorrhagic fever and rapid death within 7–14 days
following infection in humans and nonhuman primates (Hoenen
et al., 2006). There are at least five different species of EBOV—
Zaire, Sudan, Ivory Coast, Reston, and the recently identified
Bundibugyo virus (Towner et al., 2008)—having different pat-
terns of pathogenicity in nonhuman primates and man (for
example, EBOV-Reston causes no disease in man, whereas
EBOV-Zaire is highly lethal). Several animal models have been
developed to study the pathogenesis of filoviruses, including
mouse, guinea pig, hamster and nonhuman primate models
(Bowen et al., 1978; Bray et al., 1998; Connolly et al., 1999; Ryab-
chikova et al., 1996). Adult mice are resistant to naturally occur-162 Cell Host & Microbe 6, 162–173, August 20, 2009 ª2009 Elseviring isolates of EBOV. However, a mouse-adapted variant of the
Ebola Zaire virus is lethal when injected via the intraperitoneal
route of infection, but not other routes (Bray et al., 1998). The
natural reservoir of EBOV is unknown, but it is clear that the
infection of nonhuman primates and humans is an accidental
dead-end event and that none of the physiologic abnormalities
that occur during its course are the result of evolutionary adap-
tation of the virus to humans (Warfield et al., 2009). The resis-
tance of other species such as rodents may allow for determina-
tion of the differences in the susceptibility between different
accidental hosts. The interaction between the virus and immune
cells plays a critical role in the pathogenesis of this disease.
During the early stage of infection, the virus infects cells of the
monocytic lineage, including dendritic cells (DCs), monocytes,
and macrophages, whereupon these cells die or become
nonfunctional and lose their ability to stimulate antigen-specific
T cells (Mohamadzadeh et al., 2007). As the disease progresses,
there is increased release of proinflammatory cytokines, lympho-
cyte apoptosis, and spread of the virus to nonlymphocytic cell
types such as hepatocytes (Mohamadzadeh, 2009; Mohamad-
zadeh et al., 2007). Thus, multiple mechanisms have been shown
to contribute to EBOV pathogenesis.
Protein tyrosine phosphatases (PTPs) are critical regulators of
signal transduction and include a set of 107 genes within the
human genome (Alonso et al., 2004). Among these is CD45, an
abundant protein expressed in nucleated cells of hematopoietic
origin (Thomas, 1989). The primary role of CD45 is regulation of
antigen-receptor signaling of T and B cells via dephosphoryla-
tion of the Src family kinases (SFKs) (Alexander, 2000; Hermiston
et al., 2003; Thomas and Brown, 1999). CD45 can act both as
a positive and negative regulator of SFKs, depending on the
nature of the stimulus, the cell type involved, and the develop-
mental stage of the cells (Alexander, 2000; Hermiston et al.,
2003; Thomas and Brown, 1999). In addition to its role in regu-
lating intracellular signaling, CD45 is thought to play a role in
mediating cell-cell contact by modulating integrin-mediated
adhesion (Roach et al., 1997). Thus, CD45 is a pleiotropic medi-
ator of lymphocyte function.
We recently observed that mice expressing intermediate
levels of CD45 were protected against the highly virulent Ames
strain of B. anthracis, a gram-positive spore-forming bacterium
(Panchal et al., 2009). To explore the beneficial effects ofer Inc.
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gate whether evolutionarily distinct pathogens share a conver-
gent host pathway that could serve as a common therapeutic
target, mice expressing differential levels of CD45 were chal-
lenged with EBOV. In this study, we show that reduced CD45
expression levels protect mice from the lethal effects of EBOV
infection. Mechanistic studies of mice challenged with EBOV
revealed that reduced CD45 expression levels retained the
ability to properly regulate early gene expression and inflamma-
tion, as well as generated a robust protective immunity response.
All of these concerted changes contributed to reduced apo-
ptosis and rapid viral clearance, leading to the survival of the
mice.
RESULTS
Mice Expressing Reduced CD45 Levels Survive
Ebola Challenge
The pathogenesis of the mouse-adapted EBOV-Zaire infections
in mice largely resembles that in guinea pigs and nonhuman
primates (Bradfute et al., 2007, 2008; Bray et al., 1998), although
subtle differences in coagulopathy have also been observed
(Gibb et al., 2001). Therefore, to explore the role of reduced
CD45 expression in EBOV pathogenesis, we utilized mice engi-
neered to express a range of CD45 levels (11%, 22%, 36%,
62%, and 77% of the wild-type level) and mice with a point muta-
tion C817S, inactivating CD45 phosphatase activity but express-
ing 62% (CSV10+/) or 100% (CSV10+/+) of the wild-type CD45
protein, were utilized (Table 1). These cell-surface CD45 expres-
sion levels were determined by flow cytometry using erythro-
cyte-depleted blood cells (Figure 1A) and based on comparison
of mean fluorescence intensity with wild-type controls. The dif-
ferent mice groups were challenged with > 3000 LD50 of
mouse-adapted EBOV. Mice expressing 11%–77% CD45 levels
were protected from lethal EBOV challenge, with a survival rate
of 90%–100%. In contrast, the CD45100%, CD450%, CSV10+/,
and CSV10+/+ mice did not survive EBOV challenge (Figure 1B).
However, a delay in the mean time to death was observed in
CD450% and CSV10 (+/ and +/+) mice.
Table 1. Genotype of the Transgenic and HeterozygousMice and
Corresponding Percentage of CD45 Expression
Genotype % CD45 Expressionb Text Designation
KO/ 0 CD450%
B+/ 11 CD4511%
B+/+ 22 CD4522%
F+/ 36 CD4536%
het+/ 62 CD4562%
F+/ E+/ 77 CD4577%
WT+/+ 100 CD45100%
CSV10+/a 62 CSV10+/
CSV10+/+a 100 CSV10+/+
E indicates the endogenous allele of normal mice.
a Cysteine-to-serine point mutation (C817S) in founder mouse V10 inac-
tivating the CD45 phosphatase activity.
b All expression levels represent means with variation of ± 3%.Cell HFunctional Consequences of Reduced CD45 Expression
To investigate whether reduced CD45 expression affects the
entry, replication, or budding of the virus, splenocytes harvested
from CD45100%, CD4562% and CD450% mice were infected
exvivowithEBOV, and viral titersweremeasured byplaqueassay.
As shown in Figure 1C, similar viral titers were obtained from
splenocytes expressing different levels of CD45. Thus, changes
in CD45 expression levels had no effect on viral replication.
The control and clearance of EBOV infection has been shown
to correlate with effective humoral and T-cell-mediated
responses, as mice vaccinated with Ebola virus-like particles
(VLPs) require both B cells and CD8+ T cells for protection
against mouse-adapted EBOV infection (Warfield et al., 2005).
Accordingly, mice that survived EBOV challenge developed
EBOV-specific antibodies (Figure 1D), and upon rechallenge
with EBOV, a 100% survival rate (20/20) was observed for
mice expressing a range of reduced CD45 levels (data not
shown). Furthermore, CD8+ T cell responses against defined
EBOV, GP, NP, and VP40 epitopes were observed by day 7
post-EBOV infection (data not shown).
Protective Immunity in EBOV-Infected CD4562% Mice
To understand the role of reduced CD45 expression during EBOV
infection, we performed a time course study to monitor functional
and cellular changes at both the transcript and protein levels
(Figure 2A). Chemo/cytokine analysis of blood plasma indicated
that MCP-1, FGF, IFN-g, IL-4, IL-10, and IL-12 were induced
upon viral infection (day 3 and/or 5) in both the CD4562% and
CD45100% mice (Figure 2B). A significant decrease (p < 0.05) in
IL-4 levels was observed 3 days after infection in CD4562% mice
versus CD45100% mice, and the levels of this cytokine were abol-
ished by day 5 in both groups of mice. The levels of the regulatory
cytokine IL-10 at day 3 were higher in CD45100% compared to
CD4562% and completely abrogated by day 5 postinfection in
CD45100% mice. Thus, these data suggested that the initiation
of optimal immunity in CD4562% mice was achieved by regulated
expression of IL-10 upon EBOV infection, which otherwise can
suppress ongoing antiviral immunity (Couper et al., 2008).
Moreover, staining of splenocytes showed a significant
increase (p < 0.05) in the percentage of CD11b+ CD11c macro-
phages and Ly6G+ granulocytes at 5 days after EBOV challenge
in CD4562% versus CD45100% mice (Figure 2C). In blood, the per-
centage of activated CD8+ CD44high+ T cells increased dramati-
cally (p < 0.05) at 5 days after challenge in CD4562% mice when
compared to CD45100% mice (Figure 2D). The CD4562% mice
had constitutively elevated percentages of activated T cells,
and these increased levels were maintained through day 5 in
both spleen and blood. The time course study suggested that
the immune responses in CD4562% mice were altered following
EBOV infection, resulting in an increased percentage of macro-
phages and granulocytes. Collectively, these data suggested
that reduced CD45 levels might heighten the homeostasis of
immune cells in favor of protective immunity during filoviral
infection.
Viral Clearance and Reduced Apoptosis
in EBOV-Infected CD4562% Mice
EBOV clearance is controlled by functional innate and adaptive
immune responses (Mohamadzadeh et al., 2007). Accordingly,ost & Microbe 6, 162–173, August 20, 2009 ª2009 Elsevier Inc. 163
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Reduced CD45 PTPase Protects Ebola-Infected MiceFigure 1. Reduced CD45 Expression Protects EBOV-Infected Mice but Does Not Affect Viral Replication Ex Vivo
(A) CD45 expression levels of transgenic and heterozygous mice. Peritoneal macrophages and cells isolated from spleen or lymph node from the wild-type
(CD45100%) and mice with reduced CD45 expression levels were stained with FITC-conjugated anti-CD45 antibody and were analyzed by flow cytometry.
(B) Mice expressing reduced levels of CD45 (11%–77% CD45 expression) were protected following infection with EBOV. The CD45100%, CD450%, or CSV10
(+/+, 100%) or CSV10 (+/, 62%) mice having inactivated CD45 phosphatase activity did not survive EBOV infection.
(C) Splenocytes harvested from 100%, 62%, and 0% CD45-expressing mice were infected (MOI = 1) ex vivo with mouse-adapted EBOV. At times 6, 24, 48, and
72 hr, supernatant was harvested and viral titers were determined by traditional plaque assays (Moe et al., 1981).
(D) Mice with reduced CD45 expression that survived EBOV challenge generated serum-EBOV-specific antibody responses.a time course study showed that, at 7 days following EBOV chal-
lenge, the CD4562% mice had reduced viral titers in the kidney,
liver, spleen, and serum (Figure 3A). By day 10, no EBOV was
detected in the different tissues of the CD4562% mice, suggest-
ing that a robust immune response was elicited in these mice
(Figure 3A). Similarly, immunohistochemical staining of liver,
spleen, and lymph nodes showed reduced EBOV antigen and
increased cellularity of lymphocytes in the CD4562% mice at
7 days following EBOV challenge (Figure 3B). No EBOV antigen
was detected at 10 days (Figure 3C) or 30 days (Figure 3D)
following EBOV challenge. Viral clearance was likewise observed
in all other reduced-CD45-expressing mice that survived EBOV
challenge (data not shown). In contrast, the CD45100% mice
failed to clear the virus and succumbed to the pathogen between
7 and 8 days following EBOV challenge. These studies indicated
that the cellular integrity and observed active cellular homeo-
stasis might have resulted in the viral clearance in CD4562% mice.
EBOV infection is also associated with induced apoptosis of
lymphocytes (Mohamadzadeh et al., 2007). To detect apoptosis,
we stained tissues from the time course study using the TUNEL
technique. TUNEL staining of spleen samples from CD45100%
and CD4562% mice on day 5 (Figure 3E) following EBOV chal-
lenge revealed apoptotic cells in red pulp areas where extrame-
dullary hematopoiesis (EMH) normally occurs. In the EMH
regions, significant cell depletion was observed on day 5164 Cell Host & Microbe 6, 162–173, August 20, 2009 ª2009 Elseviefollowing infection in both groups of mice, suggesting prior
loss or migration of cells. In the liver at day 5, there was no signif-
icant apoptosis observed in either group of mice (Figure 3F).
However, by day 7, markedly increased (38-fold change com-
pared to day 5) apoptosis was seen in the liver of CD45100%
mice. In contrast, there was much less apoptosis in the
CD4562% at day 7 in both the liver and spleen. These findings
were confirmed by analyzing apoptosis characterized by the
presence of pyknotic nuclei using H&E staining (data not shown)
and by quantitation of the TUNEL-positive cells from the immu-
nohistochemical images (Figure 3G). These data suggested
that reduced CD45 expression levels may regulate EBOV-
induced apoptosis of these cells.
Critical Role of CD8+ T Cells in Protecting CD4562%Mice
against EBOV Challenge
Two independent approaches were taken to identify the critical
cellular players responsible for the protective response in the
CD4562% mice. In one approach, Rag knockout mice expressing
62% or 100% CD45 levels were challenged with EBOV. Neither
group of mice survived EBOV challenge, suggesting that B and/
or T cells are required for the mice to survive EBOV infection
(Figure 4A). In the second approach, lymphocyte subsets were
depleted in vivo using cell-type-specific antibodies prior to
EBOV infection. As shown in Figure 4B, depletion of all T cellsr Inc.
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(A) Schematic diagram of a timeline study wherein CD45100% and CD4562% mice were either not infected or infected with 1000 pfu of mouse-adapted EBOV.
At days 0, 1, 3, and 5, four mice per group were euthanized, various tissues were harvested, and blood was collected.
(B) Cytokine and chemokine levels from the plasma of CD45100% and CD4562% mice euthanized at days 0, 1, 3, and 5 post-EBOV infection were measured using
the cytokine 20-plex luminex kit. Only those samples that showed any detectable levels of cytokines were included. The data represent the averages of four mice
per group per time point ± SD.
(C) Splenocytes isolated from mice euthanized at days 0, 1, 3, and 5 following EBOV infection were stained for cell-surface and activation markers and were
analyzed by flow cytometry. The data represent the averages of four mice per group per time point ± SE.
(D) Blood cells collected from mice euthanized at days 0, 1, 3, and 5 post-EBOV infection were stained for cell-surface and activation markers and were analyzed
by flow cytometry. The data represent the averages of four mice per group per time point ± SE.using CD90.2 (a Thy1.2 antibody) or depletion of CD8+ T cells
resulted in increased mortality of the CD4562% mice to EBOV
challenge. In contrast, minimal susceptibility was observed
following CD4+ T cell depletion, whereas depletion of NK
subsets with NK1.1 antibody or treatment with IgG2b control
antibody had no effect on mice survival.
Activated CD8+ T cells secrete interferon g (IFN-g) to modulate
immune function. To determine whether IFN-g played a role in
protection of CD4562% mice from EBOV infection, a neutralizing
IFN-g antibody was used. Depletion of IFN-g resulted in suscep-
tibility of CD4562% mice to EBOV infection (Figure 4C), suggest-
ing that this cytokine played a critical role in induced T cell
immune responses against EBOV in CD4562% mice. Together,
these studies suggested that CD8+ T cells and IFN-g play
a pivotal role in controlling infection in the CD4562% mice.
Early Control of Gene Regulation in EBOV-Infected
CD4562% Mice
To gain insight into the changes in gene regulation elicited upon
EBOV infection, we used Affymetrix gene chip arrays to compare
gene expression in splenocytes from CD45100% and CD4562%Cell Homice. Based on gene expression patterns, the variable genes
were grouped into 16 clusters (Figure 5A). The clusters contained
genes associated with cellular immune processes, signaling,
cell-cycle, complement coagulation cascade, biosynthesis/
metabolism, ubiquitous genes involved in several cascades,
and genes of unknown function (Table S1 available online). Inter-
estingly, gene expression at day 1 following EBOV challenge in
CD45100% mice was more similar to day 3 postinfection than
preinfection. In contrast, at day 1 following EBOV infection, the
CD4562% mice maintained gene expression patterns similar to
day 0. The differences in gene expression patterns between
the CD45100% and CD4562% splenocytes were less apparent at
day 3 following infection, and by days 5 and 7, they became
very similar. At day 9, when wild-type mice had succumbed to
the disease, the pattern in CD4562% mice remained similar to
the day 7 patterns of CD45100% and CD4562% mice. The pattern
at days 11 and 13 in the CD4562% mice became similar to that
of day 0 CD45100% or CD4562% mice. These results suggested
that, in CD45100% mice, subversion of the cell transcriptional
machinery during the early stages of EBOV infection (day 1)
might represent a major factor leading to death of the mice. Inst & Microbe 6, 162–173, August 20, 2009 ª2009 Elsevier Inc. 165
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(A) Single cells were derived from kidney, liver, spleen, and serum of the EBOV-infected CD45100% and CD4562% mice on days 1, 3, 5, 7, 10, 16, and 21. Viral titers
were measured using plaque assays (Moe et al., 1981). The data represent averages of four mice per group per time point ± SD.
(B) Immunohistochemical images of liver, spleen, and mesenteric lymph node from CD45100% and CD4562% mice euthanized at 7 days after EBOV infection and
stained with anti-EBOV antibody. Scale bar, 100 um; 203 magnification.
(C) CD4562% mice euthanized at 10 days after EBOV infection and stained with anti-EBOV antibody. Scale bar, 100 um; 203 magnification.
(D) CD4562% mice euthanized at 30 days after EBOV infection and stained with anti-EBOV antibody. Scale bar, 100 um; 203 magnification.
(E) TUNEL staining of spleen from CD45100% and CD4562% mice euthanized at 5 and 7 days after EBOV challenge. Scale bar, 100 mm; 203 magnification.
(F) TUNEL staining of liver from CD45100% and CD4562% mice euthanized at 5 and 7 days after EBOV challenge. Scale bar, 100 mm; 203 magnification.
(G) For quantitation of TUNEL staining, we acquired histology images as three separate black and white photos taken successively with a blue, green, and red
filter on a Nikon E800 microscope with a SPOT RT camera. The color overlay function of MetaMorph imaging software (Molecular Devices Corporation, Down-
ingtown, PA) was used to recombine the separate black and white images into a color image. To quantitate the number of apoptotic cells, black and white images
taken with a green filter were each adjusted to an identical threshold value. The MetaMorph software ‘‘count cells’’ application was used to enumerate TUNEL-
positive cells.CD4562% mice, early control of gene regulation likely provided
the appropriate antiviral responses leading to regulated inflam-
mation, immune costimulation, and survival.
Functional and Canonical Pathways Modulated
by EBOV-Infected CD4562% Mice
To gain further insight into the changes in gene regulation upon
EBOV infection, we examined Gene Ontology (GO) Biological
Process annotations for genes that were significantly different166 Cell Host & Microbe 6, 162–173, August 20, 2009 ª2009 Elseviebetween CD45100% and CD4562% mice at each time point
(posterior probability of no change, p < 1E10 using the empir-
ical Bayes; Kendziorski et al., 2003). The primary biological
functions that were significantly enriched (p < 0.05 by Fisher’s
exact test) among genes differentially expressed between the
CD45100% and CD4562% (p < 1E10) over the course of EBOV
infection included immune and inflammatory responses,
chemotaxis, cell cycle, apoptosis, and antiapoptosis (Table 2).
In particular, the number of differentially expressed genesr Inc.
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chemotaxis were high on day 0 (before challenge) and day 5
following EBOV infection. Cell-cycle genes were significantly
(p = 3.0E4) enriched at day 1, whereas an increased number
of apoptotic and antiapoptotic genes were observed late in the
infection process (day 7). This gene expression data supported
our tissue pathology observations that indicated increased
homeostasis and cellularity, as well as a concomitant increase
in apoptosis on day 5 and a decreased apoptosis on day 7 in
the CD4562% mice during the middle to late stages of EBOV
infection.
Additionally, the expression results were analyzed using the
Ingenuity Pathway Analysis software (Ingenuity Systems, http://
www.ingenuity.com). Ingenuity-defined canonical signaling
Figure 4. CD4562% Mice Depleted of T Cells or IFN-g Succumbed to
EBOV Infection
(A) Wild-type control mice and Rag/ mice expressing either 100% or 65%
CD45 levels all succumbed to EBOV challenge.
(B) CD4562% mice depleted of CD8+ T cells or all T cells (CD90.2) using specific
antibodies succumbed to EBOV infection.
(C) CD4562% mice treated with IFN-g-neutralizing antibody succumbed to
EBOV infection.Cell Hpathways that were overrepresented (Fisher’s exact test) among
genes that differed between the CD4562% and CD45100% mice at
day 1 after infection included IL-10 signaling, LXR/RXR activa-
tion, p53 signaling, and cell-cycle regulation pathways (Fig-
ure 5B). Of great interest was the IL-10 signaling pathway, as
increased levels of this cytokine have previously been reported
in EBOV-infected humans during the first few days of clinical
illness. However, they all succumbed to the lethal infection
(Hutchinson and Rollin, 2007; Villinger et al., 1999). Our array
data showed reduced IL-10 expression throughout the course
of EBOV infection in the CD4562% mice when compared to
CD45100% mice (Figure 5C). A statistically significant reduction
in IL-10 expression was observed only at days 3 (p = 7.8E5
by empirical Bayes; Kendziorski et al., 2003) and 7 (p = 0.029)
following EBOV infection. However, a significant fraction of the
genes within the IL-10-signaling pathway exhibited altered
expression levels in the CD4562% mice at day 1 (p = 6.0E4 by
Fisher’s exact test; Figure 6A). Gene array analysis thus
suggests that reduced CD45 levels may, in part, regulate
immune mechanisms via IL-10 signaling, which is important for
regulating or suppressing T cell responses.
DISCUSSION
In this study, we show that a range of reduced CD45 expression
levels (11%–77%) resulted in a protective effect that allowed
mice to survive EBOV infection. Furthermore, this effect was
shown to be dependent on CD45 phosphatase activity, as
mice with reduced expression levels of phosphatase-inactive
CD45 succumb to the pathogen. CD4562% mice demonstrated
reduced viral titers in the kidney, liver, spleen, and serum 7
days following EBOV challenge, with no EBOV detected by day
10, suggesting that an unusually robust immune response eli-
cited in CD4562% mice might have allowed them to control the
viral infection and subsequently survive EBOV challenge. Fur-
thermore, significantly less cellular apoptosis was observed in
both the livers and spleens of these mice relative to CD45100%
mice.
Based on prior studies, it is clear that quick onset of innate
immune responses matched with balanced inflammation (Moha-
madzadeh et al., 2006) and T cell immunity (particularly CD8+
T cells) are pivotal for the clearance of EBOV infection (Bradfute
et al., 2008). Our data indicated that CD8+ T cells and IFN-g are
critical players in clearing EBOV infection in CD4562% mice. We
observed that CD4562% mice had constitutively elevated per-
centages of activated T cells and macrophages and that these
increased levels were maintained through day 5 in both the
spleen and blood. In addition, our analysis suggested that inter-
mediate CD45 levels might have controlled the inflammatory
mechanisms by way of lowered IL-10 expression, which would
lead to a heightened T cell response. Furthermore, depletion of
all T cells, CD8+ T cells, or IFN-g (a product of CD8+ T cells)
increased mortality of CD4562% mice following EBOV challenge.
It is known that a CD8+ T cell immune response is generated
even during lethal EBOV infections, and adoptive transfer of
these cells protects naive mice from EBOV challenge (Bradfute
et al., 2008). Our studies are consistent with a model in which
the function and development of EBOV-specific CD8+ T cells is
accelerated in the CD4562% mice.ost & Microbe 6, 162–173, August 20, 2009 ª2009 Elsevier Inc. 167
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(A) Heat map showing variable genes in splenocytes of CD45100% and/or CD4562% mice at days 0, 1, 3, 5, 7, 9, 11, and 13 (d0, d1, d3, d5, d7, d9, d11, and d13)
post-EBOV infection. The heat map is of log2 expression values in splenocytes for 227 genes with coefficient of variation > 1.4. Genes and samples are arranged
by dendrograms created with agglomerative nesting, and genes are assigned to 16 main clusters (colored bars). Clusters smaller than three genes are not
numbered (white bars).
(B) The five main canonical pathways that were most significantly enriched among the genes with different expression levels in CD45100% and CD4562% mice at
1 day after infection and identified from the Ingenuity Pathway Analysis library.
(C) Expression differences between CD45100% and CD4562% for IL-10 during EBOV infection. Values are expressed as log2(CD45
62%/CD45100%). P values repre-
sent posterior probability of no change by empirical Bayes. The statistically significant p values are shown with an asterisk (*).Exactly how CD4562% mice generate this unusually rapid/
robust immune response is uncertain. However, our microarray
analysis suggests that CD4562% mice were able to bypass
the dramatic downregulation of gene expression elicited in
CD45100% mice following EBOV challenge. Specifically, gene
expression in clusters 2 and 3 was observed to be downregu-
lated on day 1 following EBOV challenge in CD45100% mice. In
contrast, on day 1 following EBOV infection, CD4562% mice
maintained gene expression patterns similar to those observed
on day 0. These results indicated that lower expression levels
of CD45 prevented EBOV subversion of the cell transcriptional168 Cell Host & Microbe 6, 162–173, August 20, 2009 ª2009 Elsevimachinery during the early stages of infection, suggesting that
failure to control transcriptional regulation may represent a major
factor leading to death in CD45100% mice. These findings could
be the basis for future studies to determine whether CD45 may
play a controlling role in the wide variety of outcomes of Ebola
virus infection, such as the resistance of mice to natural filovirus
isolates.
In addition to the observed increased number of CD8+ T cells
in CD4562% mice, our gene expression analysis indicated that
increased trans-endothelial migration of effector CD8+ T cells
to sites of viral infection might be influenced by CD45 levels.er Inc.
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Day 0 Day 1 Day 3 Day 5 Day 7
GO Term P Genes P Genes P Genes P Genes P Genes
Immune response 4.3E06a 10 1.9E01 6 3.0E01 6 5.1E04a 9 5.4E01 1
Inflammatory response 1.2E12a 13 1.4E01 4 6.8E01 2 1.9E04a 7 1.0E00 0
Chemotaxis 6.5E05a 5 8.1E02a 3 6.9E01 1 3.5E04a 5 1.0E00 0
Antiapoptosis 2.8E01 1 5.4E01 1 6.0E01 1 7.9E02 2 4.4E04a 3
Apoptosis 2.7E01 4 6.0E01 6 1.9E01 10 5.3E01 4 3.1E02a 4
Cell cycle 3.1E01 4 3.0E04a 17 1.5E01 11 5.7E01 4 1.4E01 3
Enrichment of selected GO Biological Process annotations among genes differentially expressed between CD45100% and CD4562% mice (p < 1E10).
The number of genes, with indicated GO annotations, and one-tailed Fisher’s exact p value for overrepresentation within the set of differentially
expressed genes are shown for each time point.
a p < 0.05.T cell migration is regulated by differential expression of various
adhesion molecules and chemokines (Thomsen et al., 2003). In
our study, EBOV infection did not modulate the gene expression
of integrin family members or selectins in either the CD45100% or
CD4562% mice (data not shown). However, expression of intra-
cellular adhesion molecule 4 (ICAM4) was significantly higher
in CD4562% compared to CD45100% at days 1 (p = 3.7E08),
3 (p = 1.0E23), and 5 (p = 1.3E7) following EBOV challenge,
which may have reduced or delayed T cell activation and differ-
entiation (Figure 6B). In contrast, the vascular cell adhesion
molecule-1 (VCAM-1) expression was lower in CD4562% at
days 1 and 5 following EBOV infection than in CD45100% mice.
Furthermore, CD4562% mice had significantly reduced expres-
sion of chemokine receptors, including CCR1 (days 0 and 1),
CCR3 (days 0, 1, and 3), CXCL1 (days 0 and 1), and CXCL3
(days 0, 1, 5, and 7), following EBOV challenge (Figure 6B).
In contrast, expression of CXCR3 was significantly higher
(p = 7.5E4) at day 0 in CD4562% mice but declined to that of
CD45100% mice on days 1, 3, 5, and 7 following EBOV infection.
Thus, a balance between the expression levels of the
appropriate adhesion molecules and chemokines may critically
regulate lymphocyte migration to the site of infection and thereby
influence the efficiency of the antiviral response in CD4562%
mice.
How CD45 expression levels influence the antiviral response
and its underlying molecular mechanism is unclear. Depending
on the stimulus and the cell type, the role of CD45 in signal trans-
duction varies. For example, the role of CD45 in regulating acti-
vation of Src family kinases, such as p56/59hck and p53/56lyn in
macrophages, is distinct from its role in regulating the leukocyte-
specific protein tyrosine kinase p56lck during lymphocyte antigen
receptor signaling. Recently, McNeill et al. (McNeill et al., 2007)
showed that differential CD45 expression levels appear to
control the sensitivity of T cell signaling. Wild-type expression
levels of a single CD45RO isoform were critical for dephosphor-
ylation of pTyr394 of p56lck, whereas intermediate levels of the
CD45RO isoform were effective at dephosphorylating the pTyr-
505 of p56lck. In our study, the observed protective immunity eli-
cited by intermediate CD45 levels may be a consequence of
differential regulation of phosphorylation (at pTyr-505 and
pTyr-394) of p56lck (McNeill et al., 2007; Zamoyska, 2007).
In vitro and in vivo mechanistic studies that monitor changes in
the sensitivity of Src signaling in different cell types before andCell Hoafter EBOV infection, although technically challenging, would
be the key to understanding how differential CD45 levels regu-
late innate and adaptive immune responses.
The activities of virus-induced cellular mediators, including
IFNs, cytokines, and intracellular signaling molecules, are con-
trolled at multiple levels to provide an effective antiviral state.
Based on our results, we propose a model wherein reduced
CD45 expression regulates multiple mechanisms at different
stages of EBOV infection (Figure 6C). Our studies suggest that
homeostatic immune cell proliferation, enhanced cell trafficking
and migration, regulated inflammation, and early control of
gene expression related to disease pathogenesis collectively
may contribute to reduced apoptosis, viral clearance, and
survival of the EBOV-infected CD4562% mice. Furthermore, the
timing, location, interaction with binding partners, and signal
intensity of the cellular, molecular, and immune responses all
act in concert with the development of the host protective regu-
latory response in the CD4562% mice challenged with EBOV.
Previously, we showed that intermediate levels of CD45
expression reduced apoptosis of B. anthracis-infected macro-
phages and protected mice from anthrax pathogenesis (Panchal
et al., 2009). Mechanism-based studies suggested that the
protection provided by reduced CD45 levels resulted from regu-
lated immune cell homeostasis that might have diminished the
impact of apoptosis during the infection. Thus, in both the Ebola
and B. anthracis infection models, reduced CD45 expression
seems to regulate apoptosis by way of immune function.
Although it is presumed that diverse pathogens elicit divergent
molecular and cellular responses in mammalian hosts, these
studies suggest that these phylogenetically distant pathogens
likely converge at a singular, CD45-mediated process. However,
whether or not similar gene regulatory events and/or signaling
pathways are influenced by reduced CD45 expression in these
distinct infection models remains to be investigated.
The similar ability of reduced CD45 levels to confer resistance
to these two dissimilar pathogens may prove to be of extraordi-
nary importance, as it highlights CD45 as a primary target for
rational drug design. The therapeutic benefits of totally elimi-
nating CD45 protein expression have been shown in Coxsackie
B3 viral infections that cause severe immunopathologies (Irie-
Sasaki et al., 2001), whereas anti-CD45RO antibodies suppress
the replication of human immunodeficiency virus in cultured
human microglial cells (Kim et al., 2006). On the contrary, ourst & Microbe 6, 162–173, August 20, 2009 ª2009 Elsevier Inc. 169
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(A) IL-10-signaling pathway. Bar charts adjacent to the molecules display the log2 ratio of CD45
62% to CD45100% expression levels over time.
(B) Expression differences between CD45100% and CD4562% for ICAM4, CCR1, CCR3, VCAM-1, CXCL3, and CXCR3 during EBOV infection. Values are
expressed as log2(CD45
62%/CD45100%). P values represent posterior probability of no change by empirical Bayes. The statistically significant p values are shown
with an asterisk (*).
(C) Effective immunity, homeostatic immune cell proliferation, and enhanced cell migration observed in CD4562% mice collectively contribute to reduced
apoptosis, viral clearance, and subsequent survival of mice challenged with EBOV. The timing, location, interaction with binding partners, and signal intensity
of the cellular, molecular, and immune responses is critical for the protective immunity in the reduced CD45-expressing mice.studies show that reduced expression, but not complete
knockout, of CD45 is critical for the protective phenotype fol-
lowing either EBOV or B. anthracis infection. The availability of
a mouse model expressing differential levels of CD45 (Virts170 Cell Host & Microbe 6, 162–173, August 20, 2009 ª2009 Elsevieet al., 2003; Wallace et al., 1997) would allow us to further explore
the effects and role of altered CD45 levels in these infectious
disease models. Furthermore, therapeutic targeting of the down-
stream effector molecules of CD45 in combination with CD45r Inc.
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Reduced CD45 PTPase Protects Ebola-Infected Miceitself may prove beneficial for the development of host-based
therapeutics. Importantly, the functional studies described
here provide evidence that this enzyme is a promising target
for host-based therapeutics for the treatment of a broad range
of infectious diseases.
EXPERIMENTAL PROCEDURES
Transgenic and Heterozygous Mice
All mice in this study are of the C57BL/6 genetic background. The heterozy-
gous CD4562% mice have one exon-9 knockout allele and one wild-type allele.
The CD45 transgenic mice were produced using a CD45 minigene construct
containing cDNA from exons 1b-3, the genomic sequence from exon 3 to 9
(which includes the variably spliced exons and surrounding introns), and
cDNA from exon 9 through the polyadenylation signal region in exon 33, as
described previously (Virts et al., 2003; Virts and Raschke, 2001). Three
founder transgenic mice were obtained (B, F, and H), and each was bred to
the exon-9 disrupted CD45 knockout strain (Byth et al., 1996) (obtained from
Jackson Labs, Bar Harbor, ME). The properties of the F strain have been
reported by Virts et al. (Virts et al., 2003) and include the same regulated, cell-
type-specific CD45 isoform expression as observed in wild-type mice. Trans-
genic mice containing a point mutation (C817S) in the membrane-proximal
phosphatase domain of theCD45minigene were also produced. This mutation
has been shown to abolish CD45 PTPase activity in vitro (Desai et al., 1994),
and this has been confirmed in ex vivo studies (W.C.R. et al., unpublished
data). The CSV10 transgenic mice were generated using the C817S mutant
minigene, and the transgene locus was bred onto the CD45 knockout back-
ground. A more complete description of the properties of all transgenic strains
in the knockout background, including those that express an inactive CD45
protein, will be published elsewhere (W.C.R. et al., unpublished data). The
cell-surface expression levels of CD45 in all of the knockdown mice were
determined using flow cytometry by comparison of the mean fluorescence
intensities of the lymphocyte populations to those of CD45100% wild-type
and CD450% knockout mice (Virts et al., 2003). The expression level of
CSV10 transgenic mice containing one copy of the transgene insertion locus
(CSV10+/) was 62%–65%, a level similar to that expressed by CD4562%
heterozygous mice.
The Rag knockout (Rag/) mice were obtained from Dr. Linda Bradley (Sid-
ney Kimmel Cancer Center, San Diego, CA). To generate CD4562% mice in the
Rag knockout background, CD4562% heterozygous mice (CD4562%, Rag+/+)
were mated with Rag knockout mice (CD45100%, Rag/), and offspring with
62% expression of CD45 were mated with Rag/ mice. The resulting litters
were screened by flow cytometric analysis of blood samples for 62% CD45
expression and the Rag/ phenotype (very low numbers of CD19+ cells).
Animal Studies
Mice (8- to 10-week-old) were used in this study and included both males and
females. For in vivo Ebola studies, mice were challenged via intraperitoneal
(i.p.) route with 1000 pfu of mouse-adapted Ebola Zaire virus. Mice that
survived EBOV challenge were either rechallenged or they had their blood
collected to measure anti-EBOV antibody levels in the serum by ELISA, and
their tissues were harvested for pathology, T cell responses, and viral titer
measurements (Warfield et al., 2006).
All research was conducted under an approved protocol and in compliance
with the Animal Welfare Act, as well as other federal statutes and regulations
related to animals and experiments involving animals, and adhered to princi-
ples stated in the Guide for the Care and Use of Laboratory Animals, National
Research Council 1996. The facility where this research was conducted is fully
accredited by the Association for Assessment and Accreditation of Laboratory
Animal Care International.
Flow Cytometry
Antibodies used for FACS analysis were purchased from BD PharMingen (San
Diego, CA) unless otherwise noted. Antibodies used were directly conjugated
to FITC, PE, APC, PerCP, or PECy5. Clones used in these studies included
CD45 (30-F11), CD3 (17A2), CD4 (RM4-5), CD8 (53-6.7), CD11b (M1/70),
CD11c (N418, eBioscience), CD19 (1D3), NK1.1 (PK136, eBioscience), MHCCell HoI (28-14-8), MHC II (M5/114.15.2), CD44 (IM7), and Ly6G (1A8). Cells (1 3
106) were resuspended in Fc block (anti CD16/CD32 antibody diluted in
RPMI medium containing 10% FBS), incubated on ice for 30 min, centrifuged,
and stained with appropriate combinations of labeled antibodies. After incuba-
tion on ice for 60 min, cells were washed and resuspended in 10% formalde-
hyde. FACS analysis was performed using a FACSCalibur flow cytometer (BD
Biosciences). Data were analyzed using FlowJo software. Statistical analyses
of the data were performed using the two-tailed Student’s t test.
Cytokine Detection
Plasma separated from heparinized blood was analyzed for secreted cyto-
kines using the mouse cytokine 20-plex AB Bead kit (Biosource). All analyses
were performed on a Bio-Plex workstation using accompanying software (Bio-
Rad). Statistical analysis of the data was performed using the two-tailed
Student’s t test.
Ex Vivo Viral Replication
CD45100%, CD4562%, or CD450% mouse splenocytes (1 3 106 cells/ml) were
infected with a multiplicity of infection of 0.1 of mouse-adapted Ebola virus.
Cell-free supernatants were harvested at 6, 24, 48, or 72 hr and were then sub-
jected to traditional plaque assay for determination of viral titers.
Immunohistochemical Staining
To detect the presence of EBOV in infected organs, the tissue sections were
deparaffinized, blocked in methanol-H2O2 solution for 30 min at room temper-
ature (RT), rinsed with water, and pretreated with freshly diluted Proteinase
K solution (20 mg/ml) for 15 min at RT. After blocking with the CAS block con-
taining 5% goat serum, the sections were incubated with Rabbit anti-Ebola
(994) antibody for 60 min at RT. After rinsing three times with PBS, peroxi-
dase-labeled polymer conjugated to goat anti-rabbit immunoglobulins was
added and incubated for 30 min. After rinsing with PBS, substrate-chromogen
solution was added, incubated for 5 min, rinsed with PBS, stained with hema-
toxylin, and dehydrated, and tissues were mounted with Permount.
Apoptosis in tissues was detected by the TUNEL method using the Apoptag
Plus peroxidase in situ apoptosis kit (Chemicon). Processing of the tissue
samples was carried out as described above, with the following changes. After
proteinase K treatment and washing, tissues were incubated with terminal
deoxynucleotidyl transferase (TdT) for 60 min at 37

C. The reaction was
stopped by adding stop/wash buffer and incubating for 10 min at RT. After
washing three times with PBS, the tissues were incubated with anti-digoxige-
nin-peroxidase for 30 min at RT. Color development was visualized using the
DAB substrate. Slides were counterstained with methyl green.
In Vivo Antibody Depletion
Lymphocyte subsets were depleted as described previously (Alici et al., 2007;
King et al., 2008; Wang et al., 2003; Yang et al., 2006) by i.p. injection of 300 mg
of functional grade antibodies on days 3, 1, and +3. Antibodies used to
deplete lymphocyte subsets were NK1.1 (clone PK136), CD4 (clone GK1.5),
CD8 (clone 53-6.7), CD90.2 (clone 30-H12), and a rat IgG1 isotype control,
all purchased from eBioscience (San Diego, CA).
For the in vivo IFN-g studies, 300 mg of functional grade anti-IFN-g antibody
(clone XMG1.2) or a rat IgG1 isotype control was injected i.p. on days 1, +1,
+3, +6, and +11, similar to previously reported methods (Zhong et al., 2001).
Gene Expression Studies and Microarray Analysis
Splenocytes isolated from spleen of wild-type (100%) and/or heterozygous
(62%) mice at days 0, 1, 3, 5, 7, 9, 11, and 13 were resuspended in 2 ml TRIzol
solution. The samples were stored at 70C until the RNA was purified. Total
cellular RNA was isolated as per the manufacturer’s specifications. The quality
and concentration of the RNA were determined by measuring the absorbance
at 260 and 280 nm. RNA integrity was confirmed using an Agilent 2100 Bio-
analyzer (Agilent technologies, Palo Alto, CA). The mouse genome 430 2.0
array (Affymetrix, Inc.), which consists of more than 39,000 genes in a single
array, was used. Affymetrix CEL files were preprocessed using GCRMA
(version 2.12.1) (Wu et al., 2004) in R/Bioconductor (Gentleman et al., 2004)
(http://www.bioconductor.org). Median log2 expression values within each
sample type/time point with a coefficient of variation (CV) > 1.4 were chosen
using the Bioconductor package genefilter for agglomerative hierarchicalst & Microbe 6, 162–173, August 20, 2009 ª2009 Elsevier Inc. 171
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were removed, and the probeset with the largest CV was chosen for genes with
> 1 probeset. Cluster stability was assessed using the Bioconductor package
clusterStab to suggest cluster boundaries. The probeset with the largest CV
for each Entrez identifier was chosen for upload of median log2 (CD45
62%/
CD45100% ratios) and EBarrays probabilities to Ingenuity Pathways Analysis
version 6.3 (Ingenuity Systems, http://www.ingenuity.com). GO term enrich-
ment was determined with the Bioconductor package GOstats (version
2.6.0) (Falcon and Gentleman, 2007) with annotation information from
GO.db. Analyses were performed with a significance cutoff that posterior
probability of no change < 1E10.
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Microarray data are available online at the Gene Expression Omnibus website
(http://www.ncbi.nlm.nih.gov/geo), accession number GSE17509.
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